



VITALPOINT
TECHNOLOGIES, INC.

VitalPoint Technologies, Inc.

Innovative Solutions for Mental Health and Wellness

DISCLAIMER



The information provided about projects and opportunities on this site are based on the best available information but has not been verified by VitalPoint Technologies, Inc. and is subject to change at anytime. VitalPoint Technologies does not make any warranties about the information provided herein and each respective party must do their own due diligence and verification. There are significant risks associated with investing in public company ventures including equities and ETFs (Exchange Traded Funds). The information in this presentation is for general purposes only and is not a solicitation to buy or an offer to sell any securities. VitalPoint Technologies, Inc. and any of its affiliates, employees, contractors or otherwise associated parties are not United States Securities Dealers or Brokers or United States Investment Advisers; only and unless it has been properly disclosed as such. Investing in companies such as VitalPoint Technologies, Inc. is only suitable for accredited investors. In addition, the aforementioned general information is not intended to be individual tax advice. Consult your personal tax advisor concerning the current tax laws and their applicability and effect on your personal tax situation. Nothing in this presentation contains investment advice or should be construed as such. Do your own due diligence and consult with a licensed professional before making any investment decisions. Investments are risky whether through equities or partnerships and you risk losing most if not all your money. Information provided in VitalPoint Technologies, Inc.'s published communications including but not limited to; press releases, blogs, newsletters and websites that contain forward-looking statements relating to VitalPoint Technologies, Inc. operations that are based on management's current expectations, estimates and projections about the company's current market and industries. Words such as "anticipates," "expects," "intends," "plans," "targets," "projects," "believes," "seeks," "schedules," "estimates," "budgets" and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date provided in each specific VitalPoint Technologies, Inc. corporate publication. The Company does not intend to update any of the forward-looking statements after the date of publication to conform these statements to actual results or to changes in its expectations, except as may be required by law. Based upon industry standards, investment in VitalPoint Technologies would be considered highly speculative. Important factors that could cause actual results to differ materially from those in the forward-looking statements are many.

Corporate Overview

About Us



VitalPoint Technologies is a proprietary digital health software platform focused on the use of alternative solutions during a time of significant regulatory reform, allowing for expanded access to Hemp, Cannabis, Ketamine, and Psilocybin.



Raise the standards of care using our proprietary software platform for our veterans, hospice care and mental health patients with alternative solutions to remedy the epidemic of veteran suicides, opioid addiction and treatment-resistant mental health issues.

- › AltMedRx a Colorado-based software platform set to provide digital health and personal customized solutions through alternative medicine.
- › Herban Healing an established CBD / Hemp Operator with 4 years history, that developed a proprietary and research tested medicine for anti-opioid for hospice and veterans.
- › Bloomi Labs a specially formulated all in one Hand Sanitizer and moisturizer product being researched for an interactive effect in healthcare to improve sanitation and workers comfort.



Segments

- **Research**
- **Education**
- **Labs**
- **Verification**
- **Technology**



Strategy



- Developing total services solution
- Establishing product collaborations
- Partnering with university & industry studies to advance research
- Provide research and education to public
- Developing software technology to onboard patients in need & connect them with resources
- Through software, implement accreditation process for providers and connect them with patients in need through proprietary process

Portfolio - Software



AltMedRx

- AltMedRx a Colorado-based software platform set to provide proprietary digital health and personal customized solutions.
- Focused on the use of alternative solutions during a time of significant regulatory reform, allowing for expanded access to Hemp, Cannabis, Ketamine, and Psilocybin.

Research


- Database of research reports
- Summary of critical findings
- Collaboration with real time data

Reform

- Tracking reform across each jurisdiction
- Reporting on changes to regulation
- Helping patients know their options

Access

- Connecting patients and healthcare professionals
- Onboarding medicine providers
- Improving standards and certifications



Portfolio - Products



Bloomi Labs

- BloomiClean CBD Hand Sanitizer combines our high-quality organic US-grown hemp with **70%** ethyl alcohol (no methyl) to sterilize hands and the combination of CBD, Aloe Vera and Vitamin E provides a protective layer to deliver moisture and keep skin smooth without drying out your hands.
- Research has started its 1st year with healthcare workers and will expand to test its feasibility as a premium 3 in 1 acting sanitizer, anti-inflammatory and protective layers using antibacterial and antimicrobial.



Herban Healing

- Based in Houston Texas, Herban Healing produces an award-winning lineup of health and wellness products using hemp-derived CBD across a variety of consumer categories such as oils, topicals, tinctures, coffees and teas, ingestibles, and personal care and pet products containing **0%** THC.
- Research is in its 3rd year as an anti-opioid medication alternative with hospice care providers. Results have been favorable and now expansion and accreditation of research is planned.



Why Invest?



Investing in Alternative Holistic Solutions can help individuals overcome opioid addiction amongst other additions, represents a potentially lucrative opportunity. There is a growing demand for effective treatments for depression, PTSD, opioid addiction, that can help in a number of afflictions. Additionally, many governments and organizations are providing funding to support the development such issues, which can help offset some of the costs associated with developing these alternatives.



Overall, investing in Alternative Holistic Solutions to help individuals overcome multiple issues represents an opportunity to not only generate financial returns but also to make a meaningful impact on public health. By supporting the development of new and effective treatments, investors can help to address many issues, to include the opioid crisis and improve the lives of millions of people who struggle with addiction.

Investment Potential

Legalization

Many states have current legislation for psilocybin (Oregon, Rhode Island, New Jersey) Recent legalization has brought a limelight onto the potential benefits of alternative therapies which has also brought much support from public figures such as Aaron Rodgers

Government Funding/Programs

With legalization and decriminalization of multiple alternatives government is allowing programs to be developed and creating an opportunity for funding. Working with the VA provide alternative medicine for a range of medical benefits

University Research

Partnering with universities to study the efficacy of Alternative Holistic Approaches of a range of effects from pain management to mental health. Herban Healing is seeking to establish a program with Stanford University



Provides impact investors opportunities to make a difference

Healthcare/Hospice

Partnering with healthcare providers such as Hospiced for research and development of Alternative approaches as well as strategic labs

Impact Markets

- Pain management
- Veteran healthcare
- Addiction (Anti-Opioid, alcohol, etc)
- PTSD
- Mental health
- Treatment resistant depression

Institutional Management

Management with decades of experience in healthcare investments. Establishment of independent board and independent auditor

Capitalization Plan

PreSeed - Seed Capital - IPO



The capitalization plan is to employ a **3** step process of Pre-Seed, Seed Capital and IPO. There will be **2** initial rounds of private placement through the sale of shares in the company under the terms of a form D filing.



This capital will be used to fund launch AltMedRx platform, growth of Herban Healings hospice program and research study of Bloomi Labs hand sanitizer, and fund the professional services to prepare for the seed capital to IPO process.



The entire plan is equity based and we don't intend to take on any debt or convertible notes at this stage.



Offering

Common Stock



Reg D: PreSeed (Current)

- **Round 1.**
 - › PreSeed placement via Form D of **200,000** shares @ **\$.25**
 - › **1 warrant @ \$.50**
 - › Proceeds **\$50,000 (oversubscribed)**
- **Round 2.**
 - › Preseed placement via Form D of **500,000** shares @ **\$.50**
 - › **1 warrant @ \$1.00**
 - › Proceeds **\$250,000 (active)**



Seed Capital

- **Round 3.**
 - › Seed Capital up to **\$1,000,000 +** at **\$2.00** per share.
 - › **1 warrant @ \$4.00**
- **Round 4.**
 - › Complete audit, file series A up to **\$5,000,000** pre-IPO.

Conclusion And Call To Action



The Mission of the Company is to expand an acquisition platform to integrate alternative medicine, solutions and technology focused on mental health, pain management and ongoing wellness.



Join us on this Mission and let's disrupt the healthcare industry together!

Contact



Robert Yrshus



1-512-522-0360



Bob@VitalPointTech.com



3730 Kirby Drive # 1200

Houston, TX 77098



VitalPointTech.com



Herban-Healing.com





VITALPOINT
TECHNOLOGIES, INC.

Appendix A

Management

Management



Executive Chairman

Robert Yrshus

- **40+** Years in Securities & Investment Business
- Partner in Houston Based Investment Bank
- Sales Management, Private Placement, IPO Head
- Current - Registered Investment Advisor Representative, Network 1 Advisors
- Board Member / Advisor to Startups
- Drexel University



Chief Operating Officer

Oliver Nwofia

- **25+** Years in Consulting and change management
- Entrepreneur Owner of consulting group specializing in driving operational excellence across several industries
- Prior experience with Mayo Clinic where he served as the strategy operations for the internal consulting team responsible for support the entire Mayo Clinic enterprise
- MS Harvard Medical School, MBA Northwestern University

Management contd.



Chief Customer Officer

Paul Wallace

- **20+ years** in customer operations and support, delivering on-time results.
- Led teams at L7 Informatics, Halliburton, PROS, Magento, and Alert Logic.
- Created a "Customer Advocacy Program" at Halliburton, reducing support incidents.
- Holds an MBA from Tulane University, a BA, and various certifications.
- Committed to customer satisfaction and operational efficiency.



SVP of Finance

Reema Dharani

- **15+ years** of comprehensive financial expertise
- Previously served as the Head of Finance for the Americas at Alexander Mann Solutions. Also worked as the US Sales Finance Controller and ETO Finance Business Controller at Grundfos Pumps
- Prior experience includes roles at Hartford Healthcare, CITGO Petroleum, and Rolls-Royce Energy Systems
- Holds an MBA in Finance from Franklin University, Ohio, and a Master's in Personnel Management from the University of Pune, India

Management contd.



CEO - Herban Healing

Kyle Williams

- 15+ years as an accomplished business executive and entrepreneur
- Strong background in operations and technical knowledge across diverse industries.
- CEO and Co-founder of Herban Healing, LLC
- Founder and CEO of Auto Canna, LLC
- Earned his Bachelor's Degree in Business Administration from the University of Houston in 2009




President - AltMedRX

Emil Marinov

- Over 15 years in technology and healthcare, focusing on transformative solutions and innovation.
- Founder of INTP, LLC, where he developed advanced technology solutions for diverse clients.
- Holds a B.S. in Petroleum Engineering and Computer Science from the Colorado School of Mines.
- Known for successfully completing complex projects and developing proprietary technologies, actively participates in industry conferences and workshops.

Management contd.



**Senior Advisor of
Strategic Planning**
Morgan Rabito

- Over a decade of experience in healthcare business development and strategic planning.
- Currently serving as Senior Advisor of Strategic Planning at VitalPoint Technologies, Inc..
- Previous roles include Vice President of Sales at Care Hospice. Also held positions at Compassus Hospice, Silverado Senior Living, Seasons Hospice & Palliative Care, and Tenet Healthcare
- Holds a Bachelor's in Organizational Leadership from Texas A&M University.



COO – Herban Healing
Jennifer Gilleland, LVN

- Nearly two decades of experience in healthcare and entrepreneurship.
- Exceptional organizational and management skills
- Co-Founder and COO of Herban Healing, LLC
- Former Staff Nurse at Kelsey-Seybold Clinic and HCA Healthcare
- Holds an LVN degree in Nursing from Lone Star College and certifications in Medical Cannabis from the University of Colorado, CPR/AED/First Aid.

Management & Advisors



Peter Quinn

- Investor Relations



James Smith

- CPA



- **TBD**
- Advisor (Audits/Controller)



TBD

- General Counsel

SERVICE PROVIDERS



Transfer Agent

- Pacific Stock Transfer



Legal Counsel

- Chris Dieterich



Auditor

- M&K CPAs



VITALPOINT
TECHNOLOGIES, INC.

Appendix B

Market



Why This Sector?



Pushing the boundaries of medicine is the backbone of our company. It is time to try new methods of solving problems. The CBD and Psilocybin markets are showing tremendous growth and success in research. We want to pull together several companies in a broad spectrum approach. This is an emerging market segment in its early stages of growth.

Market Overview




Psychedelics Market Expected To Hit Approx. **\$12 Billion** by **2030**.



The global complementary and alternative medicine market size was valued at USD **92.65** billion in **2021** and is expected to reach over USD **411.4** billion by **2030**, poised to grow at a CAGR of **18%** from **2021** to **2030**.

U.S. Cannabidiol Market

Size, by sales type, 2020 – 2030 (USD billion)



Grand View
Research

14.9%


U.S market
CAGR, 2023
-2030

Source

www.grandviewresearch.com

PRECEDENCE
RESEARCH

Complementary & alternative medicine market size, 2020 to 2030 (USD BILLION)



CBD For Anti-opioid



Using CBD To Treat Opioid Use Disorder

<https://youtu.be/o97DaXMywFoThe>

NIH U.S. National Library of Medicine

ClinicalTrials.gov

[Home](#) > [Search Results](#) > [Study Record Detail](#)

Oral Cannabidiol for Opioid Withdrawal

CBD May Help Mitigate Opioid Withdrawal Symptoms

Dec 22, 2022
Meg Marzella



In the midst of an opioid epidemic, CBD may help patients experiencing opioid withdrawal symptoms find relief.

There is growing evidence suggesting that cannabidiol (CBD) could potentially be added to the standard opioid detoxification regime to help mitigate symptoms of opioid withdrawal, according to a recent study published in *Cannabis and Cannabinoid Research*.¹ However, most findings that support claims like these are based on preclinical studies or are small clinical trials.

Can CBD Treat Opioid Use Disorder?

Research Strategy Targets Craving to Treat Addiction


SHARE THIS ARTICLE 

Three medication treatments for opioid use disorder are approved by the U.S. Food and Drug Administration (FDA), and they work.

But treating a complex disorder like addiction remains challenging, says neurobiologist Yasmin Hurd, Ph.D., of the Icahn School of Medicine at Mount Sinai in New York City.

"Addiction is a disorder of craving," she explains, "Many psychological, social, and environmental factors perpetuate an insidious cycle of drug use."

To prevent people with opioid use disorder from returning to drug use (relapsing), "we need to figure out how to curb craving



Psilocybin For PTSD And Depression

- ... Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD.
- ... No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization.
- ... Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery.
- ... There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD

Mental Health Solutions

The Clinical Potential Of Psilocybin



The influx of psilocybin research is fueled by compounding evidence that, when given under medical supervision in controlled conditions, psilocybin may be effective for managing various psychiatric conditions, including obsessive-compulsive disorder, alcohol use disorder and substance use disorders. It is also being investigated for smoking cessation, Alzheimer's disease, eating disorders and more.



While the list of conditions is growing, many studies so far have focused on psilocybin's potential for treating depression. Multiple clinical trials support psilocybin's ability to reduce depression symptom severity, including in people with treatment-resistant depression (i.e., failure to respond to at least **2** courses of traditional antidepressants, like SSRIs). A recent phase **2** double blind trial—the largest to date—showed that a single **25** mg dose of synthetic psilocybin administered in conjunction with psychotherapy led to significantly lower levels of depressive symptoms after **3** weeks compared to the control dose (**1** mg). How? Researchers don't quite know yet.